Please try another search
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Richard Henderson | - | - | Member of Scientific Advisory Board |
Paul Leeson | - | - | Member of Scientific Advisory Board |
Chris Cargill | 38 | 2017 | Representative Executive Officer, President, CEO & Director |
Tomohiro Tohyama | 72 | 2011 | Independent External Director |
Shinichi Tamura | 73 | 2005 | Founder & Chairman of the Board |
David Roblin | 57 | 2018 | Independent External Director |
Malcolm Weir | 65 | 2020 | Member of Scientific Advisory Board |
Kuniaki Kaga | 72 | 2018 | Independent External Director |
Rolf Kristian Berndtson Soderstrom | 57 | 2020 | Independent External Director |
Noriaki Nagai | 66 | 2019 | External Independent Director |
Peter R. Bernstein | - | - | Member of Scientific Advisory Board |
Chris Tate | - | - | Member of Scientific Advisory Board |
Roberto Solari | - | - | Member of Scientific Advisory Board |
John Parkinson | - | 2022 | Member of Scientific Advisory Board |
Duncan Richards | - | 2023 | Member of Scientific Advisory Board |
Angela J. Russell | - | 2023 | Member of Scientific Advisory Board |
Miwa Seki | 58 | 2022 | External Independent Director |
Eiko Tomita | 62 | 2023 | Independent External Director |
Sheena Radford | - | 2023 | Member of Scientific Advisory Board |
Serena Scollen | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review